Palliation of dyspnoea in advanced COPD: Revisiting a role for opioids

Thorax

Volumn 64, Issue 10, 2009, Pages 910-915

  Rocker, G ^a,f   Horton, R ^a   Currow, D ^b   Goodridge, D ^c   Young, J ^d   Booth, S ^e  

^a DALHOUSIE UNIVERSITY   (Canada)

^b FLINDERS UNIVERSITY   (Australia)

^c UNIVERSITY OF SASKATCHEWAN   (Canada)

^d New Brunswick Extra Mural Program   (Canada)

^e CAMBRIDGE UNIVERSITY HOSPITALS NHS FOUNDATION TRUST   (United Kingdom)

^f QUEEN ELIZABETH II HEALTH SCIENCES CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ANXIOLYTIC AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; CORTICOSTEROID; DIAMORPHINE; DIHYDROCODEINE; MORPHINE; OPIATE;

ANOREXIA; CAREGIVER; CHEST INFECTION; CHRONIC OBSTRUCTIVE LUNG DISEASE; COGNITIVE THERAPY; CONSTIPATION; DROWSINESS; DYSPNEA; ENVIRONMENTAL FACTOR; EXERCISE; HEADACHE; HUMAN; HYPERCAPNIA; HYPOXIA; NAUSEA; NAUSEA AND VOMITING; OXYGEN THERAPY; PALLIATIVE THERAPY; PHYSICIAN; PRIORITY JOURNAL; PRURITUS; PSYCHOSOCIAL CARE; PULMONARY REHABILITATION; QUALITY OF LIFE; REVIEW; VISUAL ANALOG SCALE; WITHDRAWAL SYNDROME;

EID: 70349682905     PISSN: 00406376     EISSN: 14683296     Source Type: Journal    
DOI: 10.1136/thx.2009.116699     Document Type: Review

References (50)

1. Murray CJ, Lopez AD. Mortality by cause for eight regions of the world: Global Burden of Disease Study. Lancet 1997;349:1269-1276 (Pubitemid 27192468)
2. Rocker GM, Sinuff T, Horton R, et al. Advanced chronic obstructive pulmonary disease: innovative approaches to palliation. J Palliat Med 2007;10:783-797 (Pubitemid 47025679)
3. Abernethy AP, Wheeler JL. Total dyspnoea. Curr Opin Support Palliat Care 2008;2:110-113
4. Goodridge D, Lawson J, Duggleby W, et al. Health care utilization of patients with chronic obstructive pulmonary disease and lung cancer in the last 12 months of life. Respir Med 2008;102:885-891
5. Curtis JR. Palliative and end-of-life care for patients with severe COPD. Eur Respir J 2008;32:796-803.
6. Spathis A, Booth S. End of life care in chronic obstructive pulmonary disease: in search of a good death. Int J Chron Obstruct Pulmon Dis 2008;3:11-29.
7. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet 2007;370:765-773
8. Gore JM, Brophy CJ, Greenstone MA. How well do we care for patients with end stage chronic obstructive pulmonary disease (COPD)? A comparison of palliative care and quality of life in COPD and lung cancer. Thorax 2000;55:1000-1006
9. Solano JP, Gomes B, Higginson IJ. A comparison of symptom prevalence in far advanced cancer, AIDS, heart disease, chronic obstructive pulmonary disease and renal disease. J Pain Symptom Manage 2006;31:58-69. (Pubitemid 43143299)
10. Elkington H, White P, Addington-Hall J, et al. The healthcare needs of chronic obstructive pulmonary disease patients in the last year of life. Palliat Med 2005;19:485-491 (Pubitemid 41430822)
11. Simpson AC, Rocker GM. Advanced chronic obstructive pulmonary disease: impact on informal caregivers. J Palliat Care 2008;24:49-54.
12. Rocker GM, Dodek PM, Heyland DK. Toward optimal end-of-life care for patients with advanced chronic obstructive pulmonary disease: insights from a multicentre study. Can Respir J 2008;15:249-254
13. O'Donnell DE, Banzett RB, Carrieri-Kohlman V, et al. Pathophysiology of dyspnea in chronic obstructive pulmonary disease: a roundtable. Proc Am Thorac Soc 2007;4:145-168 (Pubitemid 46743309)
14. Evans KC, Banzett RB, Adams L, et al. BOLD fMRI identifies limbic, paralimbic, and cerebellar activation during air hunger. J Neurophysiol 2002;88:1500-1511 (Pubitemid 35025403)
15. Lacasse Y, Brosseau L, Milne S, et al. Pulmonary rehabilitation for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(3):CD003793.
16. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008;149:869-878
17. Eaton T, Garrett JE, Young P, et al. Ambulatory oxygen improves quality of life of COPD patients: a randomised controlled study. Eur Respir J 2002;20:306-312 (Pubitemid 34905784)
18. Currow DC, Abernethy AP. Pharmacological management of dyspnoea. Curr Opin Support Palliat Care 2007;1:96-101.
19. Booth S, Wade R, Johnson M, et al. The use of oxygen in the palliation of breathlessness. A report of the expert working group of the Scientific Committee of the Association of Palliative Medicine. Respir Med 2004;98:66-77.
20. Simpson AC, Rocker GM. Advanced chronic obstructive pulmonary disease: rethinking models of care. QJM 2008;101:697-704.
21. Bausewein C, Booth S, Gysels M, et al. Non-pharmacological interventions for breathlessness in advanced stages of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008;(2):CD005623.
22. Poole PJ, Veale AG, Black PN. The effect of sustained-release morphine on breathlessness and quality of life in severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998;157:1877-1880
23. Woodcock AA, Gross ER, Gellert A, et al. Effects of dihydrocodeine, alcohol, and caffeine on breathlessness and exercise tolerance in patients with chronic obstructive lung disease and normal blood gases. N Engl J Med 1981;305:1611-1616 (Pubitemid 12169189)
24. Light RW, Muro JR, Sato RI, et al. Effects of oral morphine on breathlessness and exercise tolerance in patients with chronic obstructive pulmonary disease. Am Rev Respir Dis 1989;139:126-133 (Pubitemid 19030433)
25. Abernethy AP, Currow DC, Frith P, et al. Randomised, double blind, placebo controlled crossover trial of sustained release morphine for the management of refractory dyspnoea. BMJ 2003;327:523-528 (Pubitemid 37088495)
26. Rice KL, Kronenberg RS, Hedemark LL, et al. Effects of chronic administration of codeine and promethazine on breathlessness and exercise tolerance in patients with chronic airflow obstruction. Br J Dis Chest 1987;81:287-292
27. Runo JR, Ely EW. Treating dyspnea in a patient with advanced chronic obstructive pulmonary disease. West J Med 2001;175:197-201. (Pubitemid 32923967)
28. Jennings AL, Davies AN, Higgins JP, et al. A systematic review of the use of opioids in the management of dyspnoea. Thorax 2002;57:939-944 (Pubitemid 35316271)
29. Foral PA, Malesker MA, Huerta G, et al. Nebulized opioids use in COPD. Chest 2004;125:691-694
30. Eiser N, Denman WT, West C, et al. Oral diamorphine: lack of effect on dyspnoea and exercise tolerance in the "pink puffer" syndrome. Eur Respir J 1991;4:926-931
31. Woodcock AA, Johnson MA, Geddes DM. Breathlessness, alcohol, and opiates [letter]. N Engl J Med 1982;306:1363-1364
32. Johnson MA, Woodcock AA, Geddes DM. Dihydrocodeine for breathlessness in "pink puffers". BMJ (Clin Res Ed) 1983;286:675-677
33. Currow DC, Plummer J, Frith P, et al. Can we predict which patients with refractory dyspnea will respond to opioids? J Palliat Med 2007;10:1031-1036
34. Currow DC, Kenny B, McDonald C, et al. Multi-site open label dose ranging study to determine the minimum effective dose of sustained release morphine (SRM) for reducing refractory breathlessness. Eur J Palliat Care 2009 (in press).
35. Celli BR, MacNee W. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004;23:932-946 (Pubitemid 38807371)
36. Anon. Chronic obstructive pulmonary disease. National clinical guideline on management of chronic obstructive pulmonary disease in adults in primary and secondary care. Thorax 2004;59(Suppl 1).
37. American Thoracic Society. Dyspnea. Mechanisms, assessment, and management: a consensus statement. Am J Respir Crit Care Med 1999;159:321-340
38. Rabe KF, Hurd S, Anzueto A, et al. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: GOLD executive summary. Am J Respir Crit Care Med 2007;176:532-555 (Pubitemid 47403272)
39. Abramson MJ, Crockett AJ, Frith PA, et al. COPDX: an update of guidelines for the management of chronic obstructive pulmonary disease with a review of recent evidence. Med J Aust 2006;184:342-345
40. O'Donnell DE, Aaron S, Bourbeau J, et al. State of the art compendium: Canadian Thoracic Society recommendations for the management of chronic obstructive pulmonary disease. Can Respir J 2004;11(Suppl B):7-59B. (Pubitemid 351566057)
41. Selecky PA, Eliasson CA, Hall RI, et al. Palliative and end-of-life care for patients with cardiopulmonary diseases: American College of Chest Physicians position statement. Chest 2005;128:3599-3610
42. Lanken PN, Terry PB, Delisser HM, et al. An official American Thoracic Society clinical policy statement: palliative care for patients with respiratory diseases and critical illnesses. Am J Respir Crit Care Med 2008;177:912-927
43. Markowitz AJ, Rabow M. Management of dyspnea in patients with far-advanced lung disease. JAMA 2002;287:2261. (Pubitemid 34441942)
44. Robin ED, Burke CM. Single-patient randomized clinical trial. Opiates for intractable dyspnea. Chest 1986;90:888-892
45. Rocker GM, Young J, Horton R. Using opioids to treat dyspnea in advanced COPD: a survey of Canadian clinicians. 2008. www.chestnet.org (accessed 14 Aug 2009).
46. Booth S, Bausewein C, Higginson I, et al. Pharmacological treatment of refractory breathlessness. Expert Rev Respir Med 2009;3:21-36.
47. Dean MM. End-of-life care for COPD patients. Prim Care Respir J 2008;17:46-50.
48. Smith HS, Kirsh KL. Documentation and potential tools in long-term opioid therapy for pain. Med Clin North Am 2007;91:213-228 (Pubitemid 46275799)
49. Mercadante S, Portenoy RK. Opioid poorly-responsive cancer pain. Part 1: Clinical considerations. J Pain Symptom Manage 2001;21:144-150
50. Partridge MR. Patients with COPD: do we fail them from beginning to end? Thorax 2003;58:373-375